The Week

Moderna (MRNA) fell 4.46% this week to close at $190.01, down from $198.88 the previous Friday. The S&P 500 slipped 0.27% over the same period, leaving Moderna roughly 4.19 percentage points behind the benchmark. The stock followed a rally-and-retreat pattern: Monday opened at $195.155, Tuesday spiked to a weekly high of $208.903, then three straight sessions of selling took it to a low of $183.28 on Friday before a late bounce back to $190.01. Weekly amplitude came in at 13.13%, noticeably wider than before.

Key Events

The week was dominated by Citi’s downgrade. After gains of more than 600% in the shares, Citi cut Moderna to Sell on 30 September, arguing that the oncology pipeline expectations were overpriced and the valuation was ‘unjustifiable’. The stock dropped nearly 8% in premarket trading after the news, with intraday losses mostly in the 5% to 8% range. Some put options jumped more than 4,000% on the day.

Two more positive headlines also developed. On 1 October, discussion around a Moderna-Merck cancer vaccine briefly lifted the shares by more than 3%. After the close on 2 October, Moderna announced it would join the Nasdaq-100 Index effective 9 October, which pushed the stock higher in after-hours trading. The company also lost a US government license defence in a Northwestern patent case during the week.

Analyst Ratings

Of the institutions covering Moderna, 4 rate it Buy, 1 rates it Overweight, 15 rate it Hold, 1 rates it Underweight, and 2 rate it Sell, for a total of 23. The consensus rating is Hold, with a consensus target of $120.67, about 36.49% below the current price of $190.01. Targets range from $45 to $170, showing a wide spread of views. Within the biotechnology industry, Moderna’s rating rank is 18th out of 507 companies.

The Week Ahead

On the macro calendar, the US S&P Global services PMI final reading and ISM non-manufacturing PMI land on 5 October, followed by international trade data on 6 October and EIA crude inventory figures on 7 October. For Moderna itself, the main item to watch is the official entry into the Nasdaq-100 Index on 9 October and any associated fund flows, along with whether the cancer vaccine discussion leads to further developments.

In Short

Moderna’s pullback this week followed a steep run-up. Citi’s Sell rating and the patent-case loss were the main sources of pressure, while the Nasdaq-100 inclusion and cancer vaccine chatter offered some offset. The consensus target sits about 36% below spot, highlighting the gap between valuation and market enthusiasm. The next signals to watch are the fund flows around index inclusion and whether the oncology and cancer vaccine pipeline can produce firmer data support.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.